Skye Bioscience to Showcase Innovations at Key Conferences
SAN DIEGO, Skye Bioscience, Inc. (NASDAQ: SKYE), a pioneering clinical-stage biopharmaceutical company, is excited to announce its participation in several notable healthcare investment conferences happening in November. These events will present an opportunity for Skye to engage with investors and share insights into its ongoing commitment to advancing therapeutic pathways for metabolic health.
Upcoming Healthcare Investment Conferences
The company is scheduled to be part of the following healthcare investment gatherings:
Guggenheim Healthcare Conference
On November 11, Skye will present at the Guggenheim Healthcare Conference in Boston, beginning at 1:00 pm ET. This presentation will be an excellent chance for stakeholders to hear about Skye’s latest advancements and findings.
UBS Healthcare Conference
Following that, on November 13, the UBS Healthcare Conference in Rancho Palos Verdes will feature a fireside chat at 12:30 pm PT. This engaging format is designed to facilitate a both informational and interactive discussion regarding the company's focus and mission.
Stifel Healthcare Conference
Later in the month, on November 19, the company will again hold a presentation at the Stifel Healthcare Conference in New York at 3:00 pm ET. This conference is among the most anticipated for showcasing groundbreaking healthcare innovations.
Craig-Hallum Alpha Select Conference
On the same day, Skye will offer one-on-one meetings during the Craig-Hallum Alpha Select Conference in New York, creating further opportunities to delve into its projects and objectives.
Jefferies Healthcare Conference
Rounding out the series of conferences, Skye will conduct one-on-one meetings at the Jefferies Healthcare Conference in London from November 19–21, facilitating personalized discussions and insights.
Innovative Approaches to Metabolic Health
Skye Bioscience is dedicated to unlocking new therapeutic pathways for metabolic health by developing next-generation molecules that effectively modulate G-protein coupled receptors. Their mission aims to create first-in-class therapeutics that stand out in both clinical and commercial contexts. Skye is progressing with a Phase 2 clinical trial focused on obesity, specifically evaluating nimacimab, a negative allosteric modulating antibody that operates peripherally to inhibit CB1. This trial will also investigate the synergy of nimacimab alongside a GLP-1R agonist, known as Wegovy.
Engagement and Connectivity
These upcoming conferences not only serve as platforms for sharing Skye’s innovations but also emphasize the importance of engaging with investors and industry experts. Webcasts from these presentations will be made available on Skye's website, allowing wider reach and accessibility for those interested.
About Skye Bioscience
Skye Bioscience stands at the forefront of biopharmaceutical innovation. Their strategic approach targets biologic mechanisms with substantial scientific backing and aims to develop therapeutics that enrich the quality of life for patients dealing with metabolic conditions. Through their focused research, Skye is setting the stage for advanced solutions in healthcare.
Frequently Asked Questions
What is the focus of Skye Bioscience?
Skye Bioscience focuses on unlocking new therapeutic pathways for metabolic health through innovative biopharmaceutical developments.
When will Skye present at the Guggenheim Healthcare Conference?
Skye will present at the Guggenheim Healthcare Conference in Boston on November 11 at 1:00 pm ET.
What is nimacimab?
Nimacimab is a negative allosteric modulating antibody that Skye is testing in a Phase 2 clinical trial for obesity.
How can I access the webcasts from the conferences?
Webcasts will be accessible on Skye’s website following the presentations at the various conferences.
Is Skye Bioscience publicly traded?
Yes, Skye Bioscience is publicly traded on the Nasdaq under the ticker symbol SKYE.